Essen, Germany: Following the decision by The Ministry of Commerce of the People's Republic of China (MOFCOM) that it is closing its anti-dumping investigation against imports of methionine originating in Singapore, Malaysia and Japan, Evonik has restated its commitment to the region.
MOFCOM decided to end the investigation and will therefore not be implementing tariffs on this type of import. MOFCOM’s decision has been welcomed by Evonik and the company’s strong Chinese team will continue to serve the Chinese market with a range of quality products and services.
Dr. Emmanuel Auer, Head of Animal Nutrition Business Line at Evonik said: “We have worked closely with the Chinese authorities while they conducted their investigations. We have been completely transparent with respect to the requested data and information.
“Most importantly, our customers will continue to benefit from supply reliability and security for an essential feed ingredient for a sustainable and affordable protein supply chain. We remain fully committed to our customers in China and across the world.”
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around €2.92 billion in 2019 with about 5,300 employees. It is part of Evonik Operations GmbH.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.